Loading…
Reported covered position: U.S. House of Representatives: Rep. Ryan Costello (2015-2018)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALKERMES, INC. via ALKERMES, INC.
2026 · third_quarter · Q3
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Source: Senate LDA
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act
Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2025; Support FDA efficiency reforms
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Continuing Appropriations and Extensions Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Continuing Appropriations and Extensions Act, 2025
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2025; Support FDA efficiency reforms
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2025; Support FDA efficiency reforms
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; H.R. 4366 /S. 2127- Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; H.R. 4366 /S. 2127- Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; H.R. 4366 /S. 2127- Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; FY2024 - Military Construction, Veterans Affairs, and Related Agencies Appropriations;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; H.R. 4366 /S. 2127- Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; FY2024 - Military Construction, Veterans Affairs, and Related Agencies Appropriations;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; H.R. 2471- Consolidated Appropriations Act, 2022
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 2471- Consolidated Appropriations Act, 2022; Expand funding and flexibility to address all substance use disorders; Prescription Drug User Fee Agreement reauthorization
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R.2617 - Consolidated Appropriations Act, 2023
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R. 6833 - Making continuing appropriations for fiscal year 2023, and for other purposes
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R.2617 - Consolidated Appropriations Act, 2023
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R. 6833 - Making continuing appropriations for fiscal year 2023, and for other purposes
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: ALKERMES, INC. · Firm: ALKERMES, INC.
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; Expand funding and flexibility to address all substance use disorders;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; H.R. 2471- Consolidated Appropriations Act, 2022
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; Expand funding and flexibility to address all substance use disorders;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act
Patient access and maintain six protected classes for bipolar disorders and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2026 · second_quarter · Q2
Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Patient access and maintain six protected classes for bipolar disorders and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2026 · first_quarter · Q1
Patient access and maintain six protected classes for bipolar disorders and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Policies impacting pharmaceutical distribution and manufacturing
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2025 · fourth_quarter · Q4
Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Policies impacting pharmaceutical distribution and manufacturing
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2025 · third_quarter · Q3
Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Policies impacting pharmaceutical distribution and manufacturing
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2025 · second_quarter · Q2
Policies impacting pharmaceutical distribution
Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Policies regarding drug pricing and Most Favored Nations proposals; Medicaid statutory rebate increases;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; H.R.1 - One Big Beautiful Bill Act; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act
ALKERMES, INC. via ALKERMES, INC.
2025 · first_quarter · Q1
Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Inflation Reduction Act of 2022 implementation, Part D redesign phase-in for small companies;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026; PDUFA implementation and efficiency improvements at the FDA; H.R.1414 - Camerons Law; H.R.946 - ORPHAN Cures Act;
ALKERMES, INC. via ALKERMES, INC.
2024 · fourth_quarter · Q4
Expand funding and flexibility to address all substance use disorders;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA implementation and efficiency improvements at the FDA;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2024 · third_quarter · Q3
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; H.R. 5539 - ORPHAN Cures Act; P.L. 115-97 - Tax Cuts and Jobs Act of 2017, Orphan Drug Tax Credit; Awareness of need for transparency and patient access within the 340B program; H.R. 9029 Labor, Health and Human Services, Education Appropriations, 2025; H.R. 9026 Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R. 8580 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; H.R. 9747 Continuing Appropriations and Extensions Act, 2025 PDUFA Implementation and efficiency improvements at the FDA;
Expand funding and flexibility to address all substance use disorders;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2024 · second_quarter · Q2
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; H.R.8580 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025; PDUFA Implementation and efficiency improvements at the FDA;
Expand funding and flexibility to address all substance use disorders;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2024 · first_quarter · Q1
Expand funding and flexibility to address all substance use disorders;
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2025; Support FDA efficiency reforms
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2023 · fourth_quarter · Q4
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA efficiency reforms
Expand funding and flexibility to address all substance use disorders;
ALKERMES, INC. via ALKERMES, INC.
2023 · third_quarter · Q3
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; Expand funding and flexibility to address all substance use disorders;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act Policies impacting pharmaceutical development, reimbursement, and patient access and cost Awareness of need for transparency and patient access within the 340B program H.R. 5894/S. 2624 - Labor, Health and Human Services, Education Appropriations, 2024 H.R. 5893/S. 2321 - Commerce, Justice, Science, and Related Agencies Appropriations, 2024 H.R. 4366/S. 2127 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024 Support FDA health data privacy reforms
ALKERMES, INC. via ALKERMES, INC.
2023 · second_quarter · Q2
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; Expand funding and flexibility to address all substance use disorders;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; H.R. 4366 /S. 2127- Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2024
ALKERMES, INC. via ALKERMES, INC.
2023 · first_quarter · Q1
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; Expand funding and flexibility to address all substance use disorders;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; FY2024 - Labor, Health and Human Services, Education Appropriations; FY2024 - Commerce, Justice, Science, and Related Agencies Appropriations; FY2024 - Military Construction, Veterans Affairs, and Related Agencies Appropriations;
ALKERMES, INC. via ALKERMES, INC.
2022 · fourth_quarter · Q4
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; Expand funding and flexibility to address all substance use disorders;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R.2617 - Consolidated Appropriations Act, 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2022 · third_quarter · Q3
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; Expand funding and flexibility to address all substance use disorders;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R. 6833 - Making continuing appropriations for fiscal year 2023, and for other purposes
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2022 · second_quarter · Q2
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8294 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2023 H.R. 8256 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2023 H.R. 8262 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2023 H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023 H.R. 8238 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023 Awareness of need for transparency and patient access within the 340B program
ALKERMES, INC. via ALKERMES, INC.
2022 · first_quarter · Q1
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 2471- Consolidated Appropriations Act, 2022; Expand funding and flexibility to address all substance use disorders; Prescription Drug User Fee Agreement reauthorization
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; H.R. 2471- Consolidated Appropriations Act, 2022
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
ALKERMES, INC. via ALKERMES, INC.
2021 · fourth_quarter · Q4
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; H.R.1319 - American Rescue Plan Act of 2021 (PL 117-2) H.R.4355, S.2604 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022 H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R.4372 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2022 H.R.4505 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
ALKERMES, INC. via ALKERMES, INC.
2021 · third_quarter · Q3
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment;
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; H.R.1319 - American Rescue Plan Act of 2021 (PL 117-2) H.R.4355, S.2604 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022 H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R.4372 - Department of the Interior, Environment, and Related Agencies Appropriations Act, 2022 H.R.4505 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
ALKERMES, INC. via ALKERMES, INC.
2021 · second_quarter · Q2
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R. 955 - Medicaid Reentry Act of 2021; H.R. 1319 - American Rescue Plan Act of 2021 (PL 117-2) Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2022; Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022; Interior, Environment, and Related Agencies Appropriations Act, 2022; Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022;
Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R.1319 - American Rescue Plan Act of 2021 (PL 117-2);
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Expand funding and flexibility to address all substance use disorders;
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; H.R.955 - Medicaid Reentry Act of 2021; Expand funding and flexibility to address all substance use disorders;
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)